|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: procardia and magnesiumFrom: Glen Elrod (dr99645@yahoo.com)Thu May 15 12:03:21 2008
I understand that and even questioned our local MFM on mag. He still does occasionally. I didn't end up using it in this case and restarted her procardia the next morning, but I'm still curious from a scientific perspective how long to wait between procardia dose and magnesium start IF you were go >ing to do it. Glen
----- Original Message ---- From: Efrain Ramirez <eramirezt@coqui.net> To: Multiple recipients of list OB-GYN-L <ob-gyn-l@mail.obgyn.net> Sent: Thursday, May 15, 2008 12:30:06 AM Subject: Re: procardia and magnesium I stopped using MagS04 for TPL .. Ef Magnesium sulphate for preventing preterm birth in threatened preterm labour Crowther CA, Hiller JE, Doyle LW Bookmark this: more ... loading... please wait Summary Magnesium sulphate given to women who go into labour too early does not prevent their babies being born too soon and is associated with an increased risk of the baby dying Even short-term postponement of birth when labour begins early (before 37 weeks) can help improve outcomes for babies, as the woman can take steroid drugs to help develop the baby's lungs in a short time. Magnesium sulphate is one of the drugs used to try to stop the uterus contracting in women who go into labour too soon. The review of trials did not find that magnesium sulphate, given to women who go into labour too soon, reduced the risks of the baby being born early or developing serious health problems. More babies died when women took magnesium sulphate. This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2008 Issue 2, Copyright © 2008 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X). This record should be cited as: Crowther CA, Hiller JE, Doyle LW. Magnesium sulphate for preventing preterm birth in threatened preterm labour. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD001060. DOI: 10.1002/14651858.CD001060 This version first published online: October 21. 2002 Date of last subtantive update: August 27. 2002 Abstract Background Magnesium sulphate is used to inhibit uterine activity in women in preterm labour to prevent preterm birth. Objectives To assess the effectiveness and safety of magnesium sulphate therapy given to women in threatened preterm labour with the aim of preventing preterm birth and its sequelae. Search strategy We searched the Cochrane Pregnancy and Childbirth Group trials register (May 2002) and the Cochrane Controlled Trials Register (The Cochrane Library, Issue 2, 2002). Selection criteria Types of participants: Women thought to be in preterm labour. Types of interventions: Magnesium sulphate as the only tocolytic, administered intravenously or orally, compared with either placebo, no treatment or alternative tocolytic therapy. Types of outcome measures: Measures of effectiveness, complications, women's satisfaction with their care and health service use. Data collection and analysis Assessments of trial eligibility, quality and data extractions were done by at least two of the reviewers. Main results Over 2000 women were recruited into the 23 included trials. Only nine trials were rated of high quality for the concealment of allocation. In the magnesium sulphate versus control (all studies) no difference was seen for the risk of birth within 48 hours of treatment for women given magnesium sulphate compared with controls when using a random effects model (relative risk (RR) 0.85, 95% confidence interval (CI) 0.58-1.25, 11 trials, 881 women). No benefit was seen for magnesium sulphate on the risk of giving birth preterm (<37 weeks) or very preterm (<34 weeks). The risk of death (fetal and paediatric) was higher for infants exposed to magnesium sulphate (RR 2.82, 95% CI 1.20-6.62, 7 trials, 727 infants). There were only two fetal deaths, both in the magnesium sulphate group in one study. The six other trials reported there were no fetal deaths. No differences for total paediatric mortality were shown in the six trials with data. No beneficial effect was seen from using magnesium sulphate on the risk of other neonatal morbidity. A non-significant reduction in the risk of cerebral palsy was reported at follow up at 18 months corrected age (RR 0.14, 95% CI 0.01-2.60, 1 trial, 99 children). Authors' conclusions Magnesium sulphate is ineffective at delaying birth or preventing preterm birth, and its use is associated with an increased mortality for the infant. Any further trials should be of high quality, large enough to assess serious morbidity and mortality, compare different dose regimens, and provide neurodevelopmental status of the child.
At Wed, 14 May 2008, Glen Elrod wrote:
>
-- "I can accept failure, but I can't accept not trying." - Michael Jordan
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Jul 2 04:49:27 2008 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.